Ascentage Pharma Group International (AAPG)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress

Poster presentations from ongoing clinical trials of two core assets, olverembatinib and lisaftoclax, highlight...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026

ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026

ROCKVILLE, Md. and SUZHOU, China, May 21, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress

ROCKVILLE, Md. and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International...